These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29955061)

  • 1. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.
    Anami Y; Yamazaki CM; Xiong W; Gui X; Zhang N; An Z; Tsuchikama K
    Nat Commun; 2018 Jun; 9(1):2512. PubMed ID: 29955061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
    Amin TU; Emara R; Pal A; Aldawod H; Jiang G; Liang D; Haque Tuhin MT; Balgoname A; Patel AD; Alhamadsheh MM
    J Med Chem; 2022 Nov; 65(22):15473-15486. PubMed ID: 36327103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery.
    Li L; Xu MZ; Wang L; Jiang J; Dong LH; Chen F; Dong K; Song HF
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12929-12937. PubMed ID: 33378043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
    Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.
    Ha SYY; Anami Y; Yamazaki CM; Xiong W; Haase CM; Olson SD; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Mol Cancer Ther; 2022 Sep; 21(9):1449-1461. PubMed ID: 35793453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
    Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
    Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
    Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates.
    Sanderson RJ; Nicholas ND; Baker Lee C; Hengel SM; Lyon RP; Benjamin DR; Alley SC
    Bioanalysis; 2016; 8(1):55-63. PubMed ID: 26647801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
    Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
    Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.